Mendes SA is a Swiss-based company founded in 2012. We are dedicated to the scientific development and distribution of innovative probiotic formulations with a proven safety profile and rigorous validation in clinical studies. This allows us to provide identifiable and traceable products from their conception to marketing. Our adaptability to the changing world of probiotics and their uses is confirmed by the numerous publications of studies conducted in a wide range of therapeutic applications, historically starting from gastroenterology (IBD, IBS), liver diseases and extending over the years to HIV, gynecology, autism, depression and many more.
The World Health Organization defines probiotics as ‘live organisms, which when administered in adequate amounts, confer a health benefit to the host’. All of our products contain a specific blend of bacterial strains that have demonstrated their safety and efficacy in experimental and clinical studies.
In 2007 the Human Microbiome Project (HMP) was undertaken to understand the human microbiome and its role in health and disease. Results from the HMP, along with robust scientific evidence generated by a global network of independent investigators and researchers, have shown that an imbalance in the gut bacteria (dysbiosis) contributes to the development of numerous chronic conditions.
Evidence has also supported the use of probiotics in health and disease, having shown a positive impact in the medical fields of gastroenterology, hepatology, gynaecology, oncology, infectious diseases and the central nervous system. The search for microbiome genetic signatures to predict disease incidence, progression and response to treatment is a rapidly growing discipline in translational medicine.
Thus, microbiotic therapies have provided a new frontier in the field of medicine. The probiotic market has gained considerable momentum, with a predicted market of $10 billion by 2026*.